Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation

Cancer Biology and Therapy

Volumn 8, Issue 19, 2009, Pages 1815-1825

  Moschos, Stergios J ^a   Dodd, Nicole R ^a   Jukic, Drazen M ^a   Fayewicz, Shelley L ^a   Wang, Xiaolei ^a   Becker, Dorothea ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

ATM; DNA damage checkpoint; Ionizing radiation; Melanoma

Indexed keywords

ATM PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; IONIZING RADIATION; MELANOMA; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; IMMUNOBLOTTING; MELANOMA; NEOPLASM STAGING; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 73549118073     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.19.9435     Document Type: Article

References (29)

1. Smith AP, Weeraratna AT, Spears JR, Meltzer PS, Becker D. SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions. Cancer Biol Ther 2004; 3:104-9.
2. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421:499-506.
3. DiTullio RA, Jr., Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002; 4:998-1002.
4. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000; 1:179-86.
5. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268:1749-53.
6. Shiloh Y, Kastan MB. ATM: genome stability, neuronal development, and cancer cross paths. Adv Cancer Res 2001; 83:209-54.
7. Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O'Neill TB, et al. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000; 405:477-82.
8. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
9. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
10. O'Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene 2007; 26:7816-24.
11. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-45.
12. Shiotani B, Zou L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol Cell 2009; 33:547-58.
13. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64:9152-9.
14. Petrini JH, Walsh ME, DiMare C, Chen XN, Korenberg JR, Weaver DT. Isolation and characterization of the human MRE11 homologue. Genomics 1995; 29:80-6.
15. Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 2007; 26:7749-58.
16. Roesch A, Becker B, Bentink S, Spang R, Vogl A, Hagen I, et al. Ataxia telangiectasia-mutated gene is a possible biomarker for discrimination of infiltrative deep penetrating nevi and metastatic vertical growth phase melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:2486-90.
17. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001; 11:71-7.
18. Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z, et al. Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 2005; 280:23262-72.
19. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
20. Smith GC, Divecha N, Lakin ND, Jackson SP. DNA-dependent protein kinase and related proteins. Biochem Soc Symp 1999; 64:91-104.
21. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316:1160-6.
22. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, Reis C, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16:715-24.
23. Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P, et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. Embo J 2006; 25:5775-82.
24. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9:759-69.
25. Gurley KE, Kemp CJ. Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Mol Cancer Res 2007; 5:1312-8.
26. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo J 1989; 8:3685-91.
27. Wang Y, Rao U, Mascari R, Richards TJ, Panson AJ, Edington HD, et al. Molecular analysis of melanoma precursor lesions. Cell Growth Differ 1996; 7:1733-40.
28. Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, et al. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene 2007; 26:4216-25.
29. Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 2006; 5:1375-82.